Core Viewpoint - Haineng Technology plans to invest 21 million yuan in Anyipu (Suzhou) Medical Technology Co., Ltd. through a combination of equity transfer and capital increase, aiming to enhance its business layout in the mass spectrometry product sector [3][4]. Investment Details - The investment consists of two parts: 7 million yuan for acquiring 1.6393% equity from existing shareholders and 14 million yuan for subscribing to the new registered capital of 19.3688 million yuan [3][4]. - After the transaction, Haineng Technology is expected to hold 3.85% of Anyipu's equity [3][4]. Financial Overview of Anyipu - Anyipu, established in March 2021, focuses on the R&D, production, and sales of mass spectrometers, with applications in semiconductor testing, biomedicine, food safety, and environmental monitoring [4][5]. - Financial projections indicate that Anyipu will achieve a revenue of 41.8749 million yuan in 2024 and 35.2890 million yuan from January to September 2025, with total assets of 120 million yuan and net assets of 103 million yuan as of September 2025 [4][5]. Shareholding Structure - Prior to the capital increase, Anyipu's registered capital was 8.4392 million yuan, which is expected to rise to 8.6329 million yuan post-investment [5]. - Zhang Xiaohua remains the largest shareholder, increasing his stake from 38.37% to 40.69% after the capital increase, while Haineng Technology will hold 3.85% [5][6]. Strategic Importance - This investment is a significant move for Haineng Technology to establish a foothold in the mass spectrometry market, which is experiencing strong demand in strategic emerging sectors such as semiconductors and biomedicine [6][7]. - The collaboration is expected to create synergies in technology R&D, manufacturing, and sales channels, enhancing overall market competitiveness [6][7].